Immunomedics’ cancer treatment fails to win accelerated approval from the FDA

Immunomedics Inc said on Thursday the U.S. Food and Drug Administration declined to grant accelerated approval for its breast cancer treatment, sacituzumab.

The company said it will request a meeting with the agency and work closely with the health regulator in its effort to launch the treatment as soon as possible.

“The issues related to approvability in the CRL (complete response letter) were exclusively focused on Chemistry, Manufacturing and Control matters and no new clinical or preclinical data need to be generated,” Immunomedics Chief Executive Officer Michael Pehl said.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Sandra Maler)

  • Related Posts

    • Pharma
    • August 1, 2025
    • 7 views
    Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

    The headline equity benchmarks ended with significant losses today, as investors turned cautious following the U.S. imposition of steep tariffs on multiple trade partners and the reaffirmation of a 25%…

    • Pharma
    • August 1, 2025
    • 45 views
    Karnataka issues order to merge Ayush drug dept with State FDA

    Karnataka government has issued order on the merger of the Ayush (Ayurveda, Unani, Siddha Homeopathy) Drug Licensing Authority / Drug Enforcement Division & Drug testing Laboratories with State Food and…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

    Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

    Karnataka issues order to merge Ayush drug dept with State FDA

    Karnataka issues order to merge Ayush drug dept with State FDA

    Orchid Pharma buyback rights to novel antibiotic; stock up 5%

    Orchid Pharma buyback rights to novel antibiotic; stock up 5%

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram